HK Stock Market Move | Kangnaoya (02162) rises more than 4% Seasonal allergic rhinitis IL-4R biologic drug Supbridabab monovalent monoclonal antibody approved for marketing.

Kanoya (02162) rose more than 4%, as of the time of writing, up 4.11% at 32.9 Hong Kong dollars, with a trading volume of 8.4294 million Hong Kong dollars. On the news front, on February 7th, Kanoya announced that their self-developed new drug, Conyade (Dupilumab), had been approved by the National Medical Products Administration for the treatment of Seasonal Allergic Rhinitis (SAR). This is the third indication approved for Conyade, following its approval in September and December 2024 for the treatment of moderate to severe atopic dermatitis and chronic rhinosinusitis with nasal polyps in adults. It has become the first IL-4R biologic approved for the treatment of Seasonal Allergic Rhinitis worldwide, providing a breakthrough treatment option for patients.